Swati Chopra is a Principal Correspondent at The Quint. With over 15 years of experience, she specializes in arts and entertainment, particularly focusing on the film industry and filmmaking, while also exploring themes in medicine and healthcare. Swati's insights have been featured in The Quint and BMJ.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
India (National)
Not enough data
Swati Chopra predominantly covers entertainment news with a focus on Bollywood, film industry, actors, movies, interviews, and box office performance. She regularly includes expert commentary and breaking news in her articles.
Given Swati's coverage attributes and topics covered, she is likely to be receptive to pitches that offer exclusive access to celebrities for interviews or events. Additionally, experts who can provide unique insights into the Bollywood industry trends or analysis of box office performances may catch her attention.
As Swati does not have a specified geographic focus but appears to cover global entertainment news related to Bollywood and the film industry as a whole.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Swati Chopra
Madhuri Dixit's unwavering confidence has made her one of Bollywood's most beloved stars
Jaideep Ahlawat on nepotism in the industry, the audience expectations, and working with Dharmendra in this episode of 'Tell Me All'
By: Swati Chopra
Taapsee on the industry for demanding perfection from female-led films while average male-led films thrive.
By: Swati Chopra
Director Anubhuti Kashyap chose London for 'Accused' to avoid commentary on queer relationships.
The cast of 'Kartavya' on detachment and building a life beyond the industry Published A a
By: Swati Chopra
A conversation with Imtiaz Ali, Vedang Raina and Sharvari ahead of their upcoming film 'Main Vaapas Aunga'
By: Swati Chopra
Bollywood stars call the shots. But can they also be shown the door—or simply 'banned'?
Madhuri Dixit on choosing family over fame, breaking marriage ‘rules' and playing a chaotic mother in 'Maa Behen'
Karisma Kapoor says getting projects and achieving fame was far more difficult before social media
By: Sharon Madigan, Christopher Gee, Ronan Kearney, Scott Morrison, Andrew Murray, Conor Mccann, Phil Walmsley, Swati Chopra, Nick Clement, Andrew Hall
Objective To map current strategies for weight loss in hip and knee osteoarthritis (OA), with emphasis on the emerging role of glucagon-like peptide-1 receptor agonists (GLP-1-RAs) as tools in achieving weight loss and impacting symptoms, disease progression and perioperative outcomes in individuals with obesity.Design Scoping review conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) framework and methodological guidance from the Joanna Briggs Institute and Arksey and O’Malley.Data sources PubMed, Web of Science, Directory of Open Access Journals, Scopus, ProQuest Central (1 January 2010 to 18 August 2025).Eligibility criteria Included studies focused on adults (≥18 years) with obesity and hip or knee OA, examined weight-loss strategies (nutritional, physical activity, surgical or pharmacological) including GLP-1-RAs.Results Of 199 included studies, 36 (18.1%) directly assessed GLP-1-RAs and of these, 14/36 (38.9%) reported original data. Evidence was heavily skewed towards knee OA, with limited hip-specific data. Descriptive analysis revealed a narrow geographical distribution of studies and a rapidly increasing focus on GLP-1-RAs; most studies involving GLP-1-RAs (29/36, 80.6%) were published between 2024 and 2025 and were of a low level of evidence (19/36, 52.8% level 5). Randomised and cohort data in knee OA indicate that GLP-1-RAs are associated with substantial weight loss, with accompanying improvements in pain/function and reduced progression to arthroplasty. In contrast, evidence in hip OA is sparse with weaker associations.Conclusion GLP-1-RAs represent a promising adjunct for managing individuals with OA complicated by obesity. Until further evidence emerges, GLP-1-RAs should be integrated into supervised, multimodal musculoskeletal care rather than used as standalone weight-loss agents.No data are available.
